Express News | Summary of Shareholding changes on December 24.

BreakingsDec 24 22:26

Express News | Yifang Biology: The company and its wholly-owned subsidiary are involved in a second-instance lawsuit.

BreakingsDec 24 19:15

Express News | Yifang Biotechnology: Shareholders intend to reduce their shareholding by no more than 2.8% of the company's shares.

BreakingsDec 24 19:15

Yifang Biotechnology (688382): Excellent clinical data for TYK2 inhibitors, multiple pipelines have continuous delivery capability.

Befotinib and KRAS G12C inhibitors have been approved and are expected to enter a phase of commercial expansion. Befotinib for the treatment of NSCLC in first and second-line therapy has been included in the medical insurance catalog. The commercial aspect of the third-generation EGFR TKI, Befotinib.

TianfengDec 20 18:52

Express News | 195 companies received research from Institutions.

BreakingsDec 19 08:17

Yifang Biotechnology (688382): Focused on small molecule targeted drugs, the harvesting period of the metabolism and autoimmune pipeline is approaching.

Report summary: Yifang Biology is a biotech company focused on developing small molecule targeted drugs. The core investment logic of the company is based on the following three points: 1) The oncology pipeline can contribute stable cash flow: Beifutine and Gexorace have been completed.

The Pacific Securities Dec 6 00:00